Enzalutamide in metastatic hormone-sensitive prostate cancer: results from the international, multicentre, real-world ARON-3 study

Real-world clinical practice corroborates the findings from clinical trials, confirming the effectiveness and safety of ENZA in mHSPC patients.

Authors

Institutions

Publication Details

Journal
Prostate Cancer and Prostatic Diseases
Published
2026-01-08
DOI
https://doi.org/10.1038/s41391-025-01067-3
Primary Topic
Prostate Cancer Treatment and Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Enzalutamide in metastatic hormone-sensitive prostate cancer: results from the international, multicentre, real-world ARON-3 study

Mike Wenzel, Maria Teresa Bourlon, Ondřej Fiala, Edoardo Lenci et al.
Prostate Cancer and Prostatic Diseases
Prostate Cancer Treatment and Research
article

Enzalutamide in metastatic hormone-sensitive prostate cancer: results from the international, multicentre, real-world ARON-3 study

Mike Wenzel, Maria Teresa Bourlon, Ondřej Fiala, Edoardo Lenci, Bohuslav Melichar, Zin Myint, Pasquale Rescigno, María Natalia Gandur Quiroga, Thomas Büttner, Alonso-Gordoa Teresa, Emmanuel Seront, Jindřich Kopecký, Molina-Cerrillo Javier, Laura Bernal Vaca, Alessandra Mosca, Francesco Massari, Sarah Scagliarini, Martin Bögemann, H. Harold Li, Tomáš Büchler, A. Poprach, Álvaro Juárez, Mimma Rizzo, Matteo Santoni, Jakub Kucharz, Diana Matthews, Emmanuel S. Antonarakis, Yüksel Ürün, Alejo Rodriguez-Vida, Alessandro Rizzo, Philipp Mandell
article en

Abstract

Real-world clinical practice corroborates the findings from clinical trials, confirming the effectiveness and safety of ENZA in mHSPC patients.

Prostate Cancer and Prostatic Diseases
Goethe University Frankfurt (DE), University of Minnesota (US), Cliniques Universitaires Saint-Luc (BE), University of Kentucky (US), Ankara University (TR), Universität Hamburg (DE), Charles University (CZ), Masaryk University (CZ), University Hospital Bonn (DE), Markey Cancer Center (US), Ospedale Antonio Cardarelli (IT), Azienda Universitaria Ospedaliera Consorziale - Policlinico Bari (IT), The University of Kansas Cancer Center (US), Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (MX), University Hospital in Motol (CZ), University Hospital Münster (DE), University Medical Center Hamburg-Eppendorf (DE), Martini-Klinik (DE), Masaryk Memorial Cancer Institute (CZ), Ospedali Riuniti Marche Nord (IT), Azienda USL di Bologna (IT), Clínica Santa María (CO), Hospital Del Mar (ES), Istituto Tumori Bari (IT), University Hospital Frankfurt (DE), University Hospital Hradec Králové (CZ), Velindre Cancer Centre (GB), The Maria Sklodowska-Curie National Research Institute of Oncology (PL), Candiolo Cancer Institute (IT), Istituti di Ricovero e Cura a Carattere Scientifico (IT), Hospital Jerez Puerta del Sur (ES), Instituto de Oncología de Rosario (AR), Hospital Universitario Ramón y Cajal (ES), Fundación Universitaria Sanitas (CO), Ospedale di Macerata, University of Macerata (IT), Palacký University Olomouc (CZ), Newcastle University (GB), University of Bologna (IT)
U.S. Department of Defense, National Cancer Institute
Openalex Percentile: Top 96%
Prostate Cancer Treatment and Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.